In today’s briefing:
- ResApp (RAP AU): Pfizer Coughs Up
- M3: Valuation to Further Drop as Earnings Momentum Slows Down
- Cellid (299660 KS): Promising Immunotherapeutic Platform; Well-Funded to Commercialize Pipeline
ResApp (RAP AU): Pfizer Coughs Up
- Pfizer Inc (PFE US) is Offering ResApp Health (RAP AU) shareholders up to A$0.207/share by way of a Scheme. ResApp’s Board unanimously recommends the Offer.
- ResApp is currently trialing a cough-based Covid detection tool. If the study proves satisfactory, Pfizer will outlay A$0.207/share. If not, shareholders get A$0.146/share. Pfizer initially pitched A$0.115/share.
- The results of the study are due out on the 20 June.
M3: Valuation to Further Drop as Earnings Momentum Slows Down
- M3’s shares have declined 53.2% over the last 12-months to JPY3,566 from JPY7,613 per share. Share price has lost 15% since 4QFY03/2022 earnings in April.
- The company’s Medical Platform business was a key beneficiary of pandemic which saw accelerated transformation in pharma marketing.
- However, with pandemic conditions easing off, m3’s earnings growth has begun to decelerate and we think there is further downside with weakening of core earnings.
Cellid (299660 KS): Promising Immunotherapeutic Platform; Well-Funded to Commercialize Pipeline
- Cellid (299660 KS) is developing a rich pipeline of five cell-based anticancer therapeutic vaccines, for which there are no commercialized competing products at present. BVAC-C is the lead candidate.
- BVAC-C is being developed for cervical, head and neck, anal, and certain other cancers. It is the world’s first-in-class in terms of its complex and powerful anticancer action mechanism.
- Cellid has secured government funding of KRW8.9 billion for its COVID-19 vaccine candidate. The company is accelerating clinical trial of COVID-19 booster dose candidate.
Before it’s here, it’s on Smartkarma
